27 results
Thumbnail

- D3.239 - Trimethoprim-induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpesvirus-7 (HHV-7)

Thumbnail

- D3.242 - Desensitization to ampicillin fixed drug eruption. Spotting the solution to fix the heart

Thumbnail

- D3.243 - Successful subcutaneous desensitization protocols for Canakinumab, Trastuzumab, and Triptorelin: a case series report

Thumbnail

- D3.244 - Diagnosing Drug-Induced Sweet Syndrome With Target-Like Lesions Amidst Malignancy And Infection

Thumbnail

D3.245 - Positive HLA-B*13:01 Allele in a Patient with Clinical Diagnosis of Drug Induced Eosinophilia with Systemic Symptoms (DRESS)

Thumbnail

- D3.246 - Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) induced by enoxaparin: a case report and allergology work up

Thumbnail

- D3.247 - A case report of multiple drug hypersensitivity triggered by DRESS to beta-lactamase inhibitors

Thumbnail

- D3.248 - Anaphylactic shock after indocyanine green intracervical administration

Thumbnail

- D3.249 - Delayed-Type Drug Allergy Combined with Adverse Drug Reactions

Thumbnail

- D3.250 - Macrolide Hypersensitivity: Exploring the Value of Skin and Provocation Tests in a Portuguese Case Series

Thumbnail

- D3.251 - Selective Facial Angioedema Induced by Propionic Acids: A Clinical Study of NSAID Idiosyncratic Reactions (Type 3a)

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"

Thumbnail

D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists